CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 61 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-04 | McCarthy Sean A. CEO | Grant or award · Stock Option (Right to Buy) | +390,000 | 390,000 | ||
| 2024-08-20 | Landau Jeffrey B Chief Business Officer | Option exercise | +11,250 | 123,237 | ||
| 2024-08-20 | Landau Jeffrey B Chief Business Officer | Sale | −4,181 | $1.23 | $5K | 119,056 |
| 2024-08-20 | Landau Jeffrey B Chief Business Officer | Option exercise · Performance Stock Units (PSUs) | −11,250 | 0 | ||
| 2024-08-20 | BELVIN MARCIA SVP, Chief Scientific Officer | Option exercise | +11,250 | 179,829 | ||
| 2024-08-20 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −4,181 | $1.23 | $5K | 175,648 |
| 2024-08-20 | BELVIN MARCIA SVP, Chief Scientific Officer | Option exercise · Performance Stock Units (PSUs) | −11,250 | 0 | ||
| 2024-08-20 | ROWLAND LLOYD A General Counsel | Option exercise | +11,250 | 134,978 | ||
| 2024-08-20 | ROWLAND LLOYD A General Counsel | Sale | −4,181 | $1.23 | $5K | 130,797 |
| 2024-08-20 | ROWLAND LLOYD A General Counsel | Option exercise · Performance Stock Units (PSUs) | −11,250 | 0 | ||
| 2024-08-20 | Ogden Christopher Chief Financial Officer | Option exercise | +6,875 | 110,061 | ||
| 2024-08-20 | Ogden Christopher Chief Financial Officer | Sale | −1,984 | $1.23 | $2K | 108,077 |
| 2024-08-20 | Ogden Christopher Chief Financial Officer | Option exercise · Performance Stock Units (PSUs) | −6,875 | 0 | ||
| 2024-08-20 | McCarthy Sean A. CEO | Option exercise | +37,500 | 671,749 | ||
| 2024-08-20 | McCarthy Sean A. CEO | Sale | −13,898 | $1.23 | $17K | 657,851 |
| 2024-08-20 | McCarthy Sean A. CEO | Option exercise · Performance Stock Units (PSUs) | −37,500 | 0 | ||
| 2024-06-12 | Ogden Christopher Chief Financial Officer | Grant or award | +17,500 | 103,186 | ||
| 2024-06-12 | Ogden Christopher Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2024-05-15 | Young Matthew P. Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2024-05-15 | Su Zhen Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 |
Page 5 of 27 · 529 trades